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Levosimendan in Cardiac Surgery
To the Editor: Landoni et al. (May 25 issue)1 
examined levosimendan administration versus 
placebo for patients requiring hemodynamic 
support after cardiac surgery. In their trial (Levo-
simendan to Reduce Mortality in High Risk Car-
diac Surgery Patients: A Multicenter Randomized 
Controlled Trial [CHEETAH]), they found no sig-
nificant difference in mortality between the two 
groups. The investigators aimed to include pa-
tients with shock after cardiac surgery and cardio-
pulmonary bypass. However, many of the patients 
were likely to have distributive shock (i.e., 57.7% 
received epinephrine, 45.3% norepinephrine, and 
15.2% dopamine) rather than cardiogenic shock 
(28.3% received dobutamine and 12.5% enoximone) 
(Table S5 in the Supplementary Appendix, avail-
able with the full text of the article at NEJM.org). 
The vasodilator effect of levosimendan2 may be 
detrimental in those with vasoplegia after car-
diopulmonary bypass. Indeed, hypotension, pos-
sibly due to low diastolic and coronary perfusion 
pressure,3 is associated with 30-day mortality in 
multivariate analysis (P = 0.005), whereas low car-
diac output is not. In addition, the investigators 
did not target their drug administration to either 
cardiac output or markers of tissue hypoxia (e.g., 
lactate level, mixed venous oxygen saturation, or 
the venoarterial carbon dioxide gradient). Inotro-
pic drugs are likely to exert only detrimental ef-
fects on myocardium4 if an increase in cardiac 
output, along with oxygen delivery,5 is not accom-
panied by evidence of improvement in oxygen 
consumption.
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To the Editor: The trial by Landoni et al. ran-
domly assigned cardiac-surgery patients with post-
operative cardiovascular dysfunction to receive 
levosimendan or placebo. The trial showed no 
significant beneficial effects on postoperative 
outcome, similar to the findings of the trial by 
Mehta et al. (May 25 issue).1 In the latter trial 
(Levosimendan in Patients with Left Ventricular 
Systolic Dysfunction Undergoing Cardiac Surgery 
Requiring Cardiopulmonary Bypass [LEVO-CTS]), 
levosimendan was administered just after anes-
thesia induction to patients with preoperative 
cardiac dysfunction.
Pharmacokinetic and pharmacodynamic stud-
ies suggest that the steady-state concentration of 
levosimendan is reached within 4 to 8 hours 
after initiation of the infusion and remains con-
stant over a period of 24 hours.2 Active plasma 
metabolites can be detected after 12 hours, with 
a peak in 48 to 78 hours; such metabolites con-
tribute further to the hemodynamic effects of the 
drug.2 The hemodynamic effects of levosimendan 
increase progressively, reaching a plateau after 
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3 to 6 hours.3,4 Taking into account these pharma-
cologic features, there is still room for a study 
to define the real effect on clinical outcome of 
levosimendan administered preoperatively — for 
instance, beginning the day before surgery.
Alessandro Putzu, M.D. 
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Cardiocentro Ticino 
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Dr. Landoni and colleagues reply: We dis-
agree with Dell’Anna and colleagues that most 
patients enrolled in our trial had a primary vaso-
plegic syndrome rather than predominant myo-
cardial dysfunction as the cause of their hemo-
dynamic instability. In fact, 498 of 506 patients 
(98.4%) had reasons different from receipt of 
norepinephrine alone for inclusion in the trial, 
and a subgroup analysis did not identify any sub-
group effect between patients receiving norepi-
nephrine at randomization and those not receiv-
ing it (Fig. S4B in the Supplementary Appendix of 
our article). We acknowledge that it is difficult to 
separate a degree of inflammatory vasoplegia 
from cardiogenic shock as the cause of hypo-
tension after cardiac surgery. However, despite 
the use of epinephrine in nearly 60% of patients, 
dobutamine in nearly 30%, dopamine in 15%, 
and enoximone in more than 10% and a mean pul-
monary-artery occlusion pressure of 15.5 mm Hg, 
the mean cardiac index at randomization was 
only 2.2 liters per minute per square meter of 
body-surface area. This is not the hemodynamic 
picture of primary vasodilatory shock, as seen in 
the recent Angiotensin II for the Treatment of 
High-Output Shock (ATHOS-3) trial.1
We also disagree with the unproven notion that 
clinicians would not have targeted their therapy 
to lactate level, mixed venous oxygen saturation, 
cardiac index, and other clinical, physiological 
and biochemical markers of perfusion. Although 
we did not collect the specific information, such 
a notion assumes, without evidence, that literally 
hundreds of clinicians dealing with these patients 
in multiple intensive care units would have failed 
to adjust treatment according to such principles.
We agree, however, with Dell’Anna and col-
leagues that levosimendan-induced hypotension 
could have attenuated its possible beneficial ef-
fects. Such a hypotensive effect is a property of 
this drug and one of its major limitations as an 
inotropic agent in cardiac surgery.
We appreciate the view of Putzu and col-
leagues that the administration of levosimendan 
beginning the day before surgery may optimize 
its inotropic effects. However, given the lack of 
effect seen in CHEETAH, the LEVO-CTS trial, 
and the Levosimendan in Coronary Artery Re-
vascularization (LICORN) trial,2 it is difficult to 
imagine that the additional gain from more 
prolonged administration before surgery would 
have a clinically important effect.
Giovanni Landoni, M.D.
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E. Meshalkin National Medical Research Center 
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Drs. Mehta and Alexander reply: We concur 
with Putzu et al. that a future study to evaluate 
the efficacy of levosimendan among patients un-
dergoing cardiac surgery with cardiopulmonary 
bypass may be warranted, particularly given the 
favorable trend for lower 90-day mortality ob-
served with levosimendan in the LEVO-CTS trial. 
We agree that one reason levosimendan may not 
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have worked in the LEVO-CTS trial was that it 
was started soon before surgery (median, 20 min-
utes). However, the “pharmacokinetic and pharma-
codynamic” information that Putzu et al. provided 
to support their hypothesis for a new study was 
reported in patients with heart failure1-3 rather 
than those undergoing cardiac surgery with car-
diopulmonary bypass, for whom pharmacokinetic 
data with levosimendan are unavailable and may 
differ. Until the pharmacokinetic data from the 
LEVO-CTS trial or other studies in cardiac sur-
gery are available, the assumption that the phar-
macokinetic properties of levosimendan are 
similar in patients with heart failure and those 
undergoing cardiac surgery with cardiopulmo-
nary bypass should be made with caution.
Rajendra H. Mehta, M.D., 
John H. Alexander, M.D., M.H.S.
Duke Clinical Research Institute 
Durham, NC 
raj . mehta@ duke . edu
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Midostaurin in FLT3-Mutated Acute Myeloid Leukemia
To the Editor: Stone et al. (Aug. 3 issue)1 found 
that adding midostaurin to a standard chemo-
therapy regimen containing daunorubicin at a 
dose of 60 mg per square meter of body-surface 
area significantly prolonged overall and event-free 
survival among patients with acute myeloid leuke-
mia (AML) and a FLT3 mutation (point mutation 
in the tyrosine kinase domain [TKD] or internal 
tandem duplication [ITD] mutation) as compared 
with placebo plus standard chemotherapy.
In a previous study, a nonsignificant trend for 
benefit beyond 12 months was shown in patients 
with a FLT3 mutation of the ITD subtype who 
received daunorubicin at a dose of 90 mg per 
square meter as compared with a dose of 60 mg 
per square meter.2 It is more appropriate to give 
the higher dose of daunorubicin to patients with 
the ITD mutation,3 and anthracycline intensifica-
tion may be beneficial in such patients.4 Recently, 
high-dose daunorubicin (90 mg per square me-
ter) was found to be more effective than idaru-
bicin (12 mg per square meter) in patients with 
a FLT3 mutation of the ITD subtype.5 These data 
raise the questions of whether daunorubicin alone 
at a dose of 90 mg per square meter would in-
duce better responses and outcomes than adding 
midostaurin to daunorubicin at a dose of 60 mg 
per square meter and whether the combination 
of midostaurin and the higher dose of daunoru-
bicin would further improve the outcomes of 
patients with FLT3-mutated AML.
A. Emre Eskazan, M.D.
Istanbul University 
Istanbul, Turkey 
emreeskazan@ hotmail . com
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To the Editor: The interaction among muta-
tions in a polyclonal disease such as newly diag-
nosed AML determines the prognosis. In FLT3-
mutated AML, co-occurring mutations such as 
in NPM1 and DNMT3 alter the outcome consid-
erably.1 Again, FLT3 inhibition by lestaurtinib was 
greater when NPM1 was also mutated.2 There-
fore, clarification of the NPM1 status in the 
trial by Stone et al. would facilitate data interpre-
tation.
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on February 6, 2018. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
